At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 13, 2026 at 07:30 ET
Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in license revenue from the Moderna settlement. Revenue surged to $179.1M from $1.8M YoY, and the company ended the quarter with $95.2M in cash. The stock will move on the magnitude of the settlement cash inflow and the FDA Fast Track designation for imdusiran, though the core business remains pre-revenue.
- Q1 2026 GAAP diluted EPS $0.87 vs consensus -$0.06 (beat by $0.93)
- Total revenue $179.1M vs $1.8M YoY, driven by $178.7M license revenue from Genevant/Moderna settlement
- Net income $169.7M vs net loss $24.5M YoY
- Cash, cash equivalents and marketable securities $95.2M as of March 31, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access